Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

Affiliations

¹ The Alfred Hospital and Monash University, Melbourne, VIC, Australia. a.wei@alfred.org.au.
² National and Kapodistrian University of Athens Medical School, Laiko General Hospital, Athens, Greece.
³ Hospital Universitario y Politécnico La Fe, Valencia, Spain.
⁴ CIBERONC, Instituto Carlos III, Madrid, Spain.
⁵ Centre Hospitalier-Le Mans, Le Mans, France.
⁶ Almazov National Medical Research Center, Saint Petersburg, Russia.
⁷ Seoul National University Hospital, Seoul, South Korea.
⁸ University Hospital Královské Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
⁹ Norton Cancer Institute, Louisville, KY, USA.
¹⁰ Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹¹ Evaggelismos General Hospital, Athens, Greece.
¹² CIUSSS-EMTL, Installation Maisonneuve-Rosemont, Montreal, QC, Canada.
¹³ Eastern Health and Monash University, Melbourne, VIC, Australia.
¹⁴ University of Pittsburgh Medical Center (UPMC) Cancer Center, Pittsburgh, PA, USA.
¹⁵ George Papanicolaou General Hospital, Thessalonica, Greece.
¹⁶ Netcare Pretoria East Hospital, Moreletapark, Pretoria, South Africa.
¹⁷ Heartlands Hospital, Birmingham, UK.
¹⁸ University of Fukui Hospital, Fukui, Japan.
¹⁹ Chinese Academy of Medical Sciences, Tianjin, China.
²⁰ AbbVie Inc, North Chicago, IL, USA.
²¹ The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Published Erratum

Andrew H Wei et al. Blood Cancer J. 2021.

. 2021 Oct 26;11(10):171.

doi: 10.1038/s41408-021-00565-6.

¹ The Alfred Hospital and Monash University, Melbourne, VIC, Australia. a.wei@alfred.org.au.
² National and Kapodistrian University of Athens Medical School, Laiko General Hospital, Athens, Greece.
³ Hospital Universitario y Politécnico La Fe, Valencia, Spain.
⁴ CIBERONC, Instituto Carlos III, Madrid, Spain.
⁵ Centre Hospitalier-Le Mans, Le Mans, France.
⁶ Almazov National Medical Research Center, Saint Petersburg, Russia.
⁷ Seoul National University Hospital, Seoul, South Korea.
⁸ University Hospital Královské Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic.
⁹ Norton Cancer Institute, Louisville, KY, USA.
¹⁰ Hubertus Wald University Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
¹¹ Evaggelismos General Hospital, Athens, Greece.
¹² CIUSSS-EMTL, Installation Maisonneuve-Rosemont, Montreal, QC, Canada.
¹³ Eastern Health and Monash University, Melbourne, VIC, Australia.
¹⁴ University of Pittsburgh Medical Center (UPMC) Cancer Center, Pittsburgh, PA, USA.
¹⁵ George Papanicolaou General Hospital, Thessalonica, Greece.
¹⁶ Netcare Pretoria East Hospital, Moreletapark, Pretoria, South Africa.
¹⁷ Heartlands Hospital, Birmingham, UK.
¹⁸ University of Fukui Hospital, Fukui, Japan.
¹⁹ Chinese Academy of Medical Sciences, Tianjin, China.
²⁰ AbbVie Inc, North Chicago, IL, USA.
²¹ The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

No abstract available

Erratum for

6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).
Wei AH, Panayiotidis P, Montesinos P, Laribi K, Ivanov V, Kim I, Novak J, Stevens DA, Fiedler W, Pagoni M, Bergeron J, Ting SB, Hou JZ, Anagnostopoulos A, McDonald A, Murthy V, Yamauchi T, Wang J, Chyla B, Sun Y, Jiang Q, Mendes W, Hayslip J, DiNardo CD. Wei AH, et al. Blood Cancer J. 2021 Oct 1;11(10):163. doi: 10.1038/s41408-021-00555-8. Blood Cancer J. 2021. PMID: 34599139 Free PMC article. Clinical Trial.